These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9799045)

  • 1. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?
    Jacob S; Rett K; Henriksen EJ
    Am J Hypertens; 1998 Oct; 11(10):1258-65. PubMed ID: 9799045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers.
    Jacob S; Balletshofer B; Henriksen EJ; Volk A; Mehnert B; Löblein K; Häring HU; Rett K
    Blood Press; 1999; 8(5-6):261-8. PubMed ID: 10803485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic considerations in the choice of therapy for the patient with hypertension.
    Black HR
    Am Heart J; 1991 Feb; 121(2 Pt 2):707-15. PubMed ID: 1671190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
    Jacob S; Rett K; Wicklmayr M; Agrawal B; Augustin HJ; Dietze GJ
    J Hypertens; 1996 Apr; 14(4):489-94. PubMed ID: 8761899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)].
    Klein W
    Z Kardiol; 1992 Jun; 81(6):295-302. PubMed ID: 1353932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers.
    Deedwania P
    J Clin Hypertens (Greenwich); 2011 Jan; 13(1):52-9. PubMed ID: 21214722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of obesity hypertension and diabetes syndrome.
    Zanella MT; Kohlmann O; Ribeiro AB
    Hypertension; 2001 Sep; 38(3 Pt 2):705-8. PubMed ID: 11566961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy in diabetic patients.
    Weidmann P; Boehlen LM; de Courten M; Ferrari P
    J Hum Hypertens; 1992 Dec; 6 Suppl 2():S23-36. PubMed ID: 1289510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of differential effects of antihypertensive agents on serum lipids.
    Brook RD
    Curr Hypertens Rep; 2000 Aug; 2(4):370-7. PubMed ID: 10981172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects.
    Teuscher AU; Weidmann PU
    J Hypertens Suppl; 1997 Mar; 15(2):S67-75. PubMed ID: 9218202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator.
    Eleftheriadou I; Tsioufis C; Tsiachris D; Tentolouris N; Stefanadis C
    Curr Vasc Pharmacol; 2011 Nov; 9(6):715-22. PubMed ID: 21470107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
    Moser M; Frishman W
    Am J Hypertens; 1998 Jan; 11(1 Pt 2):15S-22S. PubMed ID: 9503102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antihypertensive treatment and risk of coronary disease. How significant is the antihypertensive effect for metabolic factors?].
    Moan A; Os I; Hjermann I; Kjeldsen SE
    Tidsskr Nor Laegeforen; 1994 Feb; 114(4):462-4. PubMed ID: 8009486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive agents, insulin sensitivity, and new-onset diabetes.
    Sarafidis PA; McFarlane SI; Bakris GL
    Curr Diab Rep; 2007 Jun; 7(3):191-9. PubMed ID: 17547836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of antihypertensive drugs.
    Suter PM; Vetter W
    J Hypertens Suppl; 1995 Dec; 13(4):S11-7. PubMed ID: 8824682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers for hypertension.
    Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.